ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R. 5539/S. 3131, Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act H.R.7085 BioSecure Act; Issues related to the BIOSECURE Act and US manufacturing of pharmaceuticals HR 3433/S 2897, Give Kids A Chance Act Implementation of the Inflation Reduction Act (IRA) -- with specific focus on drug negotiation (orphan drug exemption language) Issues related to expanding/amending the orphan drug exclusion in IRA Issues related to the price and manufacture of inhaled medicines Issues related to the IRAs drug price negotiation program Issues related to importation of drugs Issues related to drug pricing Issues related to RSV monoclonal antibody manufacture and distribution Issues related to FDA proposed regulation of lab developed tests Issues related to pharmacy benefit managers (PBM) reform Issues related to FDA Orange Book patent listings Issues related to COVID vaccine access and reimbursement Issues related to COPD patient access through CMMI demonstration models General issues related to health equity in rare disease and clinical trials General issues related to rare disease and orphan drugs Reauthorization of the pediatric priority review voucher program Education to Hill staff on next generation propellant and PFAS AZ sustainability platform FDA modernization policy issues Reauthorization of the pediatric priority review voucher program
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CUDWORTH ARBES | — |
| KATIE JONES | — |
| LISA LANGENDERFER | — |
| ART MOTTA | — |
| CAROLINE QUAT | — |
Medicare/Medicaid MMM
HR 1503/S 2916 Prescription Information Modernization Act Amending Orphan drug exemption of the Implementation of the Inflation Reduction Act, Pub L 117-169 e-labeling - allowing FDA to finalize a rule to allow digital versions of prescriptions Medicare patient access to rare disease therapies, Part B and Part D drugs Centers for Medicare and Medicaid Innovation (CMMI) policy issues Medicare drug price negotiation Medicare Part D reform and inflation penalties Medicaid Drug Rebate Program proposed rule Value-based payment arrangements Efforts to improve coding, coverage, and access for rare disease therapies Medicaid Drug Rebate Program proposed rule, specifically the stacking rule General issues related to diagnostic reimbursement
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CUDWORTH ARBES | — |
| KATIE JONES | — |
| LISA LANGENDERFER | — |
| ART MOTTA | — |
| CAROLINE QUAT | — |
Pharmacy PHA
E-labeling Issues related to PBM reform. Issues related to the HR 7085, the BIOSECURE Act US manufacturing of pharmaceuticals
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CUDWORTH ARBES | — |
| KATIE JONES | — |
| LISA LANGENDERFER | — |
| ART MOTTA | — |
| CAROLINE QUAT | — |
Taxation/Internal Revenue Code TAX
Issues related to the deduction of research and development expenditures S.866/H.R.2673, American Innovation and R&D Competitiveness Act of 2023 Education on tax in preparation for 2025 tax legislation
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CUDWORTH ARBES | — |
| KATIE JONES | — |
| LISA LANGENDERFER | — |
| ART MOTTA | — |
| CAROLINE QUAT | — |
Copyright/Patent/Trademark CPT
Issues related to FDA Orange Book patent listings
| Lobbyist | Covered position, as disclosed |
|---|---|
| SARAH CUDWORTH ARBES | — |
| KATIE JONES | — |
| LISA LANGENDERFER | — |
| ART MOTTA | — |
| CAROLINE QUAT | — |
Insurance INS
Alternative funding programs
| Lobbyist | Covered position, as disclosed |
|---|---|
| LISA LANGENDERFER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.